Lead Product(s) : T-Guard
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Xenikos B.V
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : T-Guard (ricin toxin A conjugated mAB) is designed to reset the body's immune system in life-threatening T cell‒mediated conditions, potentially including prevention of transplant-related rejection, treatment of acute solid-organ rejection, and severe ...
Product Name : T-Guard
Product Type : Antibody
Upfront Cash : Inapplicable
June 28, 2022
Lead Product(s) : T-Guard
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Xenikos B.V
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
